



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2023





© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

September 2023

N = 7625



Health Authority	Male	Female	All
FRASER	1537	469	2006
INTERIOR	461	121	582
NORTHERN	149	80	229
VANCOUVER COASTAL	3327	455	3782
VANCOUVER ISLAND	832	167	999
	6306	1292	7598
		Unknown/not stated:	27
		Total:	7625

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (September 2018 - September 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (September 2018 - September 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (September 2018 - September 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (September 2018 - September 2023)






1.6 Percent Distribution of Active Participants by CD4 Count
(September 2018 - September 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(September 2018 - September 2023)






1.8 Active and Inactive Participants (September 2018 - September 2023)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2018 - September 2023)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2018 - September 2023)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(September 2018 - September 2023)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2018 - September 2023)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2018 - September 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2018 - September 2023)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2018 - September 2023)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2018 - September 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(September 2018 - September 2023)






1.18 Baseline CD4 for Antiretroviral First Starts
(September 2018 - September 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (September 2018 - September 2023)






1.20 Cumulative Resistance Testing Results by Resistance Category (September 2018 - September 2023)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2018 - September 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	32	4	0	4	1	980	4	<40	4
1988	32	3	0	3	1	380	3	<40	4
1989	30	50	1	51	20	510	46	<40	3
1990	28	51	1	52	28	565	50	<40	3
1991	29	37	3	40	16	525	38	<40	3
1992	29	50	5	55	22	640	51	<40	3
1993	28	115	14	129	67	550	121	<40	3
1994	27	65	11	76	38	560	66	<40	3
1995	27	117	18	135	72	545	121	<40	3
1996	25	293	48	341	172	550	314	<40	3
1997	22	259	30	289	147	600	260	<40	3
1998	22	171	37	208	121	580	186	<40	3
1999	22	141	39	180	101	580	156	<40	3
2000	22	112	26	138	76	620	120	<40	3
2001	21	107	25	132	68	620	114	<40	3
2002	20	112	25	137	81	600	129	<40	3
2003	20	133	26	159	94	615	142	<40	3
2004	19	135	36	171	103	650	159	<40	3
2005	18	168	39	207	127	690	190	<40	3
2006	17	163	41	204	114	650	181	<40	3
2007	16	219	39	258	149	670	235	<40	3
2008	15	264	59	323	195	670	288	<40	3
2009	14	285	65	350	198	620	315	<40	3
2010	13	246	68	314	173	660	276	<40	3
2011	12	311	65	376	217	680	336	<40	3
2012	11	257	63	320	183	660	285	<40	3
2013	10	247	62	309	173	680	278	<40	3
2014	9	261	45	306	165	740	277	<40	3
2015	8	255	44	299	164	730	260	<40	3
2016	7	240	50	290	157	680	248	<40	3
2017	6	194	31	225	125	680	198	<40	3
2018	5	178	47	225	125	740	197	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	220	39	259	163	690	231	<40	3
2020	3	168	54	222	139	740	180	<40	3
2021	2	181	35	216	129	610	195	<40	3
2022	1	257	48	305	201	700	287	<40	3
2023	0	232	52	284	244	530	273	<40	3
Total:		6301	1291	7592					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7492	758	1990	<40	1227	620
SEP-2022	7442	772	1787	<40	1092	636
OCT-2022	7468	778	1849	<40	1164	640
NOV-2022	7502	783	1898	<40	1202	630
DEC-2022	7544	787	1607	<40	1005	640
JAN-2023	7582	793	2051	<40	1316	650
FEB-2023	7520	809	1727	<40	1017	630
MAR-2023	7547	803	1974	<40	1213	640
APR-2023	7553	796	1761	<40	1080	630
MAY-2023	7592	786	1933	<40	1224	650
JUN-2023	7600	787	1841	<40	1088	630
JUL-2023	7583	805	1747	<40	1036	620
AUG-2023	7611	801	1814	<40	1009	630
SEP-2023	7625	795	1775	<40	1035	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	36	447
AUG-2022	787	261	59	78	49	560
SEP-2022	845	209	71	<40	53	460
OCT-2022	828	214	83	<40	62	495
NOV-2022	814	213	80	50	60	505
DEC-2022	779	236	57	<40	45	560
JAN-2023	739	287	63	<40	45	550
FEB-2023	794	231	66	<40	53	550
MAR-2023	763	243	78	<40	56	512
APR-2023	768	231	66	<40	47	560
MAY-2023	734	241	65	<40	47	440
JUN-2023	716	208	57	<40	38	445
JUL-2023	742	191	68	<40	50	565
AUG-2023	741	194	63	<40	38	595
SEP-2023	730	216	55	<40	40	510

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14660
AUG-2022	7468	787	15	17	169	172	-1	14698
SEP-2022	7423	845	13	15	146	192	-46	14726
OCT-2022	7443	828	14	16	195	171	20	14761
NOV-2022	7480	814	9	17	210	177	37	14800
DEC-2022	7511	779	19	8	213	167	31	14827
JAN-2023	7551	739	20	10	193	143	40	14862
FEB-2023	7504	794	10	11	157	205	-47	14886
MAR-2023	7531	763	15	21	197	176	27	14920
APR-2023	7531	768	13	12	175	168	0	14949
MAY-2023	7575	734	7	15	205	165	44	14993
JUN-2023	7579	716	14	17	168	164	4	15028
JUL-2023	7565	742	11	12	164	177	-14	15059
AUG-2023	7589	741	11	15	215	192	24	15104
SEP-2023	7592	730	14	6	176	161	3	15125

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	446	45	7496	8.46%	84.99%	5.95%	0.60%	100.00%
AUG-2022	643	6364	443	43	7493	8.58%	84.93%	5.91%	0.57%	100.00%
SEP-2022	663	6295	439	45	7442	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6309	439	41	7468	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6318	447	41	7502	9.28%	84.22%	5.96%	0.55%	100.00%
DEC-2022	709	6344	450	41	7544	9.40%	84.09%	5.97%	0.54%	100.00%
JAN-2023	721	6372	445	44	7582	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6317	429	39	7520	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6311	445	41	7547	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	801	6315	435	41	7592	10.55%	83.18%	5.73%	0.54%	100.00%
JUN-2023	821	6300	438	41	7600	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	845	6258	440	40	7583	11.14%	82.53%	5.80%	0.53%	100.00%
AUG-2023	866	6251	448	46	7611	11.38%	82.13%	5.89%	0.60%	100.00%
SEP-2023	881	6264	434	46	7625	11.55%	82.15%	5.69%	0.60%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 68%	3229 44%	10 25%	1219 17%	36 90%	4344 59%
AUG-2022	5 14%	2991 41%	4 11%	2261 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1179 16%	32 86%	4355 59%
SEP-2022	4 14%	2952 40%	3 11%	2195 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2950 40%	4 11%	2173 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2951 40%	3 11%	2148 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1096 15%	29 83%	4466 60%
FEB-2023	3 13%	2943 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1064 14%	21 88%	4446 60%
MAR-2023	2 6%	2935 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1050 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3656 49%	4 12%	1002 13%	30 88%	4534 61%
JUL-2023	5 16%	2920 39%	1 3%	1968 26%	0 0%	14 0%	25 81%	3680 49%	2 6%	986 13%	26 84%	4533 61%
AUG-2023	4 9%	2913 39%	1 2%	1938 26%	0 0%	14 0%	34 76%	3723 50%	9 20%	970 13%	41 91%	4567 61%
SEP-2023	2 10%	2907 39%	1 5%	1915 26%	0 0%	13 0%	16 76%	3755 50%	3 14%	955 13%	19 90%	4588 61%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	385 26%	1 100%	1028 71%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	367 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	354 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	342 25%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	0 0%	0 0%	304 24%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	0 0%	0 0%	295 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	0 0%	0 0%	284 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	0 0%	0 0%	276 23%	3 100%	914 75%	0 0%	37 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	0 0%	1 100%	272 22%	0 0%	911 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	2 50%	281 27%	0 0%	117 11%	0 0%	280 27%	2 50%	207 20%
AUG-2022	0 0%	157 15%	1 33%	276 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	182 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 27%	0 0%	197 19%
DEC-2022	0 0%	185 18%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	201 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	208 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	223 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	223 23%	0 0%	92 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	89 9%	1 100%	220 23%	0 0%	177 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	0 0%	0 0%	2 13%	2468 44%	1 7%	347 6%	0 0%	1 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	0 0%	0 0%	6 29%	2437 44%	0 0%	331 6%	0 0%	1 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	0 0%	0 0%	3 11%	2460 43%	1 4%	324 6%	0 0%	1 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	0 0%	0 0%	5 26%	2436 43%	0 0%	312 5%	0 0%	1 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	0 0%	0 0%	5 23%	2455 43%	0 0%	309 5%	0 0%	1 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	0 0%	0 0%	5 15%	2454 42%	0 0%	300 5%	0 0%	1 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 67%	2745 47%	0 0%	0 0%	7 19%	2452 42%	3 8%	297 5%	1 3%	2 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	0 0%	0 0%	6 18%	2452 42%	1 3%	294 5%	0 0%	2 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	0 0%	0 0%	6 24%	2433 42%	0 0%	281 5%	0 0%	1 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	0 0%	0 0%	6 17%	2440 41%	1 3%	280 5%	0 0%	1 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2920 49%	0 0%	0 0%	8 24%	2462 41%	1 3%	276 5%	0 0%	2 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2974 50%	0 0%	0 0%	5 22%	2464 41%	1 4%	270 4%	0 0%	2 0%	0 0%	20 0%	1 4%	307 5%
JAN-2023	23 82%	3016 50%	0 0%	0 0%	5 18%	2492 41%	0 0%	269 4%	0 0%	3 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3040 50%	0 0%	0 0%	6 25%	2476 41%	0 0%	255 4%	0 0%	2 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3084 51%	0 0%	0 0%	5 15%	2482 41%	2 6%	259 4%	0 0%	2 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	22 81%	3084 50%	0 0%	0 0%	4 15%	2498 41%	1 4%	258 4%	0 0%	2 0%	0 0%	18 0%	0 0%	274 4%
MAY-2023	28 67%	3138 51%	1 2%	3 0%	12 29%	2504 41%	1 2%	250 4%	0 0%	2 0%	0 0%	18 0%	0 0%	278 5%
JUN-2023	26 81%	3197 51%	0 0%	5 0%	6 19%	2509 40%	0 0%	249 4%	0 0%	2 0%	0 0%	18 0%	0 0%	267 4%
JUL-2023	25 83%	3219 52%	0 0%	5 0%	5 17%	2500 40%	0 0%	248 4%	0 0%	2 0%	0 0%	18 0%	0 0%	257 4%
AUG-2023	33 79%	3263 52%	0 0%	7 0%	6 14%	2498 40%	1 2%	246 4%	0 0%	2 0%	0 0%	18 0%	2 5%	255 4%
SEP-2023	15 75%	3297 52%	0 0%	8 0%	5 25%	2506 40%	0 0%	238 4%	0 0%	2 0%	0 0%	18 0%	0 0%	250 4%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently available on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	674	9.03	85	1.14
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	668	9.04	79	1.07
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	674	9.04	83	1.11
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	670	9.03	79	1.06
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	669	8.95	79	1.06
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	659	8.81	75	1.00
JUL-2022	857	11.43	699	9.32	4578	61.07	632	8.43	655	8.74	75	1.00
AUG-2022	827	11.04	692	9.24	4610	61.52	641	8.55	649	8.66	74	0.99
SEP-2022	799	10.74	691	9.29	4575	61.48	662	8.90	642	8.63	73	0.98
OCT-2022	788	10.55	673	9.01	4620	61.86	678	9.08	637	8.53	72	0.96
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	646	8.61	71	0.95
DEC-2022	774	10.26	663	8.79	4680	62.04	706	9.36	651	8.63	70	0.93
JAN-2023	750	9.89	665	8.77	4728	62.36	718	9.47	649	8.56	72	0.95
FEB-2023	715	9.51	664	8.83	4712	62.66	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	652	8.64	4735	62.74	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	707	9.31	644	8.48	4752	62.59	799	10.52	627	8.26	63	0.83
JUN-2023	676	8.89	625	8.22	4788	63.00	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.73	627	8.27	4761	62.79	843	11.12	628	8.28	62	0.82
AUG-2023	643	8.45	621	8.16	4783	62.84	864	11.35	633	8.32	67	0.88
SEP-2023	640	8.39	615	8.07	4806	63.03	879	11.53	621	8.14	64	0.84

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	12	1	3	1	1	5	440
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	12	1	2	4	2	3	265
AUG-2023	15	2	1	4	2	3	258
SEP-2023	6	1	1	0	0	3	616

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12277	3734
FEB-2022	12300	3748
MAR-2022	12328	3763
APR-2022	12357	3788
MAY-2022	12348	3777
JUN-2022	12363	3779
JUL-2022	12389	3788
AUG-2022	12410	3800
SEP-2022	12429	3809
OCT-2022	12455	3829
NOV-2022	12463	3819
DEC-2022	12440	3801
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12399	3693
JUL-2023	12426	3716
AUG-2023	12423	3698
SEP-2023	12410	3685

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7625
Sep-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Sep-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	45	61	27
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	102	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	444	602	329	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	239	322	173	
Total HA:		802	1087	582

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		802	1087	582

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	164	222	121
Male	638	865	461

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	582	56	680	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	15	8
	<5 years	6	5
	Total HSDA:	45	27
KOOTENAY BOUNDARY	10 years or more	49	32
	5 years or more	13	10
	<5 years	12	11
	Total HSDA:	74	53
OKANAGAN	10 years or more	282	204
	5 years or more	90	64
	<5 years	72	61
	Total HSDA:	444	329
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	145	106
	5 years or more	47	29
	<5 years	47	38
	Total HSDA:	239	173
Total HA:		802	582

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	500	356
5 years or more	165	111
<5 years	137	115
Total HA:	802	582

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	52	71	10	15
KOOTENAY BOUNDARY	78	138	19	41
OKANAGAN	241	1097	54	337
THOMPSON/CARIBOO/SHUSWAP	152	573	35	142
Total:	523	1879	118	535

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	12
KOOTENAY BOUNDARY	11
OKANAGAN	71
THOMPSON/CARIBOO/SHUSWAP	50
Total:	144

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	37	39	30
	35-49	102	104	67
	50+	266	373	199
	Total HSDA:	412	523	302
FRASER NORTH	20-34	140	141	101
	35-49	368	395	281
	50+	643	1027	482
	Total HSDA:	1151	1563	864
FRASER SOUTH	0-19	8	8	7
	20-34	118	120	90
	35-49	305	333	239
	50+	633	967	504
	Total HSDA:	1064	1428	840
Total HA:		2627	3514	2006

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	15	15	13
	20-34	295	300	221
	35-49	775	832	587
	50+	1542	2367	1185
Total HA:		2627	3514	2006

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	634	812	469
Male	1993	2702	1537

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2006	53	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	278	212
	5 years or more	67	39
	<5 years	67	51
	Total HSDA:	412	302
FRASER NORTH	10 years or more	720	517
	5 years or more	240	188
	<5 years	191	159
	Total HSDA:	1151	864
FRASER SOUTH	10 years or more	648	498
	5 years or more	212	163
	<5 years	204	179
	Total HSDA:	1064	840
Total HA:		2627	2006

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1646	1227
	5 years or more	519	390
	<5 years	462	389
Total HA:		2627	2006

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	150	542	31	62
FRASER NORTH	260	1633	43	223
FRASER SOUTH	228	1827	46	496
Total:	638	4002	120	781

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	203
FRASER NORTH	707
FRASER SOUTH	473
Total:	1383

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		353	526
RICHMOND	20-34	30	31	20
	35-49	57	58	46
	50+	125	182	104
	Total HSDA:	212	271	170
VANCOUVER	0-19	13	13	12
	20-34	451	465	304
	35-49	1223	1364	880
	50+	2998	5372	2143
	Total HSDA:	4685	7214	3339
Total HA:		5250	8011	3782

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	13
	20-34	509	524	340
	35-49	1351	1500	980
	50+	3376	5973	2449
Total HA:		5250	8011	3782

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	598	974	455
Male	4650	7035	3327
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3782	55	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	244	189
	5 years or more	53	44
	<5 years	56	40
	Total HSDA:	353	273
RICHMOND	10 years or more	126	98
	5 years or more	36	28
	<5 years	50	44
	Total HSDA:	212	170
VANCOUVER	10 years or more	3298	2277
	5 years or more	764	552
	<5 years	623	510
	Total HSDA:	4685	3339
Total HA:		5250	3782

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3668	2564
5 years or more	853	624
<5 years	729	594
Total HA:	5250	3782

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	188	415	36	50
RICHMOND	45	318	8	97
VANCOUVER	693	11786	222	5466
Total:	926	12519	266	5613

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	70

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	524
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		128	181
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		816	1171
Total HA:		1301	1876	999

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	110	119	71
	35-49	307	349	241
	50+	878	1402	681
Total HA:		1301	1876	999

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	217	319	167
Male	1084	1557	832

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	999	56	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	224	179
	5 years or more	72	51
	<5 years	61	52
	Total HSDA:	357	282
NORTH VANCOUVER ISLAND	10 years or more	92	71
	5 years or more	23	20
	<5 years	13	12
	Total HSDA:	128	103
SOUTH VANCOUVER ISLAND	10 years or more	508	374
	5 years or more	158	120
	<5 years	150	120
	Total HSDA:	816	614
Total HA:		1301	999

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	824	624
	5 years or more	253	191
	<5 years	224	184
Total HA:		1301	999

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	204	933	68	173
NORTH VANCOUVER ISLAND	161	286	39	71
SOUTH VANCOUVER ISLAND	226	1957	37	587
Total:	591	3176	144	831

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	109
NORTH VANCOUVER ISLAND	44
SOUTH VANCOUVER ISLAND	125
Total:	278

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	9	9	6
	35-49	16	19	11
	50+	30	39	16
	Total HSDA:	55	67	33
NORTH WEST	20-34	*	5	0
	35-49	*	38	15
	50+	*	79	36
	Total HSDA:	74	122	51
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	197	297	145
Total HA:		326	486	229

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		326	486	229

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	176	80
Male	211	310	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	229	54	545	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	18	*
	Total HSDA:	55	33
NORTH WEST	10 years or more	52	34
	5 years or more	11	9
	<5 years	11	8
	Total HSDA:	74	51
NORTHERN INTERIOR	10 years or more	110	83
	5 years or more	53	38
	<5 years	34	24
	Total HSDA:	197	145
Total HA:		326	229

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	193	131
5 years or more	70	50
<5 years	63	48
Total HA:	326	229

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	41	61	6	8
NORTH WEST	88	184	15	40
NORTHERN INTERIOR	123	507	23	191
Total:	252	752	44	239

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	20
NORTHERN INTERIOR	13
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	51	*
	THOMPSON/CARIBOO/SHUSWAP	*	52	*
	Total HA:	67	122	47
FRASER	FRASER EAST	37	52	27
	FRASER NORTH	52	95	38
	FRASER SOUTH	79	117	54
	Total HA:	168	264	119
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	53	25
	RICHMOND	6	11	5
	VANCOUVER	451	913	377
	Total HA:	483	977	407
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	83	38
	NORTH VANCOUVER ISLAND	15	29	12
	SOUTH VANCOUVER ISLAND	49	97	38
	Total HA:	112	209	88
NORTHERN	NORTH EAST	11	15	6
	NORTH WEST	33	69	21
	NORTHERN INTERIOR	71	119	56
	Total HA:	115	203	83
Total:		945	1775	744

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1140	461
Female	344	635	283

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	744	54	530	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

